- Conditions
- Clostridioides Difficile Infection
- Interventions
- Ridinilazole, Vancomycin
- Drug
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • Miami, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 173
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clostridium Difficile Infection Recurrence
- Interventions
- ART24, Placebo
- Biological · Drug
- Lead sponsor
- Adiso Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 13
- States / cities
- Palm Springs, California • Clearwater, Florida • Doral, Florida + 9 more
- Conditions
- Clostridium Difficile Infection, Infection, Communicable Diseases
- Interventions
- RBX2660
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
- Conditions
- Prostate Cancer, Urinary Tract Infection, Clostridium Difficile
- Interventions
- Ciprofloxacin
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Recurrent Clostridioides Difficile Infection
- Interventions
- REC-3964
- Drug
- Lead sponsor
- Recursion Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 115 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Toms River, New Jersey • San Antonio, Texas
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 60
- States / cities
- Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Microbiota Enrichment Program (MEP)
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Clostridium Difficile Infection
- Interventions
- Fecal Microbiota Transplant
- Drug
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Clostridium Difficile Infection Recurrence
- Interventions
- Bacillus velezensis DSM 33864, Placebo
- Dietary Supplement
- Lead sponsor
- Novozymes A/S
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Clostridium Difficile Infection
- Interventions
- RBX7455
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Clostridium Difficile Infection
- Interventions
- Comparison between GenePOC PCR and Reference Method
- Device
- Lead sponsor
- Meridian Bioscience, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Detroit, Michigan + 2 more
- Conditions
- Inflammatory Bowel Diseases, Clostridium Difficile Infection
- Interventions
- Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Clostridium Difficile
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
- Conditions
- Clostridium Infections
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 7
- States / cities
- Sacramento, California • Hamden, Connecticut • Boston, Massachusetts + 3 more
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
- Interventions
- Chlorhexidine
- Drug
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
- Conditions
- Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile Diarrhea, Antibiotic-associated Colitis, Antibiotic-associated Diarrhea
- Interventions
- GT160-246
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 58
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Clostridioides Difficile Infection, Healthcare Associated Infection
- Interventions
- GeoHAI
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Clostridium Infections, Diarrhea
- Interventions
- PAR-101/OPT-80, Vancomycin
- Drug
- Lead sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 53
- States / cities
- Gadsden, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 50 more
- Conditions
- Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
- Interventions
- VE303, Placebo
- Drug
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
- Interventions
- VE303, Placebo
- Biological
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 852 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- FMT, Antimicrobials
- Biological · Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Bacterial Infection, Clostridium Difficile
- Interventions
- Educational Intervention
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Clostridial Infection, Dysbiosis, Probiotic Therapy
- Interventions
- Fecal Microbiota Transplantation (FMT), Saline
- Procedure · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Durham, North Carolina • Nashville, Tennessee
- Conditions
- Clostridium Infections, Diarrhea
- Interventions
- Rifaximin (Xifaxan), Vancomycin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 63
- States / cities
- Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more